Biotech


  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Syncona melds two gene therapy biotechs for better shot at new nervous system treatments

    The new company, Spur Therapeutics, is getting another $50 million from Syncona to support its broadened pipeline, which targets Parkinson’s disease as well as heart conditions.

    By June 17, 2024
  • An illustration of B cells producing antibodies
    Image attribution tooltip
    Love Employee via Getty Images
    Image attribution tooltip

    New data showcase promise, growing pains of CAR-T in autoimmune disease

    One expert described trial results presented at EULAR last week as “unprecedented.” But reports of relapses in some patients drew questions about the therapies’ ultimate potential.

    By June 17, 2024
  • Explore the Trendline
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Trendline

    Emerging biotech

    New biotechs continue to emerge despite a challenging market environment that has forced venture firms to build their drug startups more cautiously.

    By BioPharma Dive staff
  • An AbbVie sign is seen on a building at the pharmaceutical company's U.S. headquarters.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie joins in latest gastrointestinal drug chase

    Following Roche, Merck and others into a hot field, the Humira maker will pay $150 million to license a preclinical TL1A antibody for IBD.

    By June 14, 2024
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Radiopharma drugmaker Telix pulls US IPO plans

    The Australia-based company had proposed raising $202 million via an initial stock sale, but withdrew its filing, citing its shares’ recent price appreciation on Australia’s stock exchange. 

    By June 14, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing

    The Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P. Morgan Private Capital closed its first fund and the FDA gave new COVID shot advice.

    By BioPharma Dive staff • June 14, 2024
  • a nurse gives a vaccination to a woman sitting in a chair
    Image attribution tooltip
    Joe Raedle/Getty Images via Getty Images
    Image attribution tooltip

    Moderna says next-gen COVID shot effective in study

    Trial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases superior, to the company’s initial COVID vaccine.

    By Kristin Jensen • June 13, 2024
  • A headshot of Peter Emtage, CEO of Santa Ana Therapeutics.
    Image attribution tooltip
    Permission granted by Versant Ventures
    Image attribution tooltip
    Emerging biotech

    Versant debuts biotech working on ‘anger management for the immune system’

    Investor enthusiasm for precision immunology medicines is providing a tailwind for Santa Ana Therapeutics, a new startup backed by Versant, GV and a16z, among others.

    By June 13, 2024
  • Pfizer's logo cast in metal.
    Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip
    Obesity drugs

    Flagship taps startup to hunt for obesity drugs that might interest Pfizer

    The venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates that Pfizer can choose to advance under a partnership it struck with Flagship last year.

    By June 12, 2024
  • Close up of conference room with glasses of water on the table with papers, armchairs and a large window.
    Image attribution tooltip
    Igor Kutyaev via Getty Images
    Image attribution tooltip

    Regenxbio CEO to step down after 15 years

    Kenneth Mills will become chair of the gene therapy developer's board while Curran Simpson, the current chief operating officer, will take his place as company head.

    By June 12, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss

    Study results indicated Avidity’s medicine muted target genes. Elsewhere, Syntis revealed obesity drug plans and Nodthera chalked up more positive data for its NLRP3 inhibitor.

    By BioPharma Dive staff • June 12, 2024
  • Image attribution tooltip

    Image courtesy of Ultragenyx.

    Image attribution tooltip

    Ultragenyx, Mereo drug reduces fractures in bone disorder study

    New data show the treatment’s effect on fractures and bone density held up over time, boosting the drug’s prospects ahead of a Phase 3 readout.

    By Kristin Jensen • June 12, 2024
  • A red magnifying glass sits on top of cash.
    Image attribution tooltip
    Pla2Na via Getty Images
    Image attribution tooltip

    Foresite, a biotech venture firm, reloads with $900M fund

    Amid some optimism for biotech startups, the firm sees opportunities to fund companies “at all stages of the productive development life cycle,” said managing director Vik Bajaj.

    By June 12, 2024
  • An illustration of human liver anatomy against a stylized background.
    Image attribution tooltip
    Rasi Bhadramani via Getty Images
    Image attribution tooltip

    Ipsen drug for rare liver disease approved by FDA

    The medicine will join Intercept’s Ocaliva as a treatment option for primary biliary cholangitis. Another drug, from the now Gilead-owned CymaBay, could be cleared for the condition by August.

    By June 11, 2024
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu

    The offering will help fund Phase 3 tests of a drug the biotech claims could be more selective and potent than Bristol’s TYK2 inhibitor.

    By June 10, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip

    Geron wins long-sought drug approval; Califf talks China, GLP-1s at BIO

    After 34 years, Geron finally has an approved medicine in Rytelo. Elsewhere, Shionogi disclosed disappointing obesity drug data and AbbVie got some good trial news.

    By BioPharma Dive staff • June 7, 2024
  • Image attribution tooltip
    Warren Little via Getty Images
    Image attribution tooltip

    GSK acquires oligonucleotide drug startup Elsie

    The deal, worth up to $50 million, adds to a pipeline GSK is building around nucleic acid drugs, including its hepatitis B candidate bepirovirsen.

    By June 6, 2024
  • People walk past a sign reading BIO 2024 in a conference center.
    Image attribution tooltip
    Gwendolyn Wu/BioPharma Dive
    Image attribution tooltip
    Emerging biotech

    As biotech recovers, venture firms’ preferences appear to shift

    Venture investment into U.S. biotechs is back at pre-COVID levels. But firms seem more selective in the companies they favor, and some are looking toward M&A rather than IPOs for an exit.

    By Updated June 6, 2024
  • An image of a periodic table entry for the chemical element lutetium
    Image attribution tooltip
    Lark Andrew Balcita via Getty Images
    Image attribution tooltip

    Germany’s ITM raises $205M as radiopharma field booms

    The funding will help ITM advance a pipeline that includes a potential competitor to Novartis' neuroendocrine cancer treatment Lutathera.

    By June 6, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

    A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study.

    By BioPharma Dive staff • June 5, 2024
  • A micrograph showing triglyceride fat accumulated inside liver cells.
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Viking says biopsy data confirm MASH drug’s benefit

    The company may look to license the experimental liver disease drug as it focuses on an obesity treatment that's shown early promise.

    By June 4, 2024
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip
    Obesity drugs

    Structure pill leads to competitive weight loss in obesity study

    Shares in the company soared by more than 50% as study data showed the pill led to similar levels of weight loss as a rival drug being developed by Eli Lilly.

    By June 3, 2024
  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    JHVEPhoto via Getty Images
    Image attribution tooltip
    ALS drug development

    Eli Lilly adds ALS drug prospect with QurAlis deal

    The alliance hands Lilly an RNA-based therapy in preclinical testing for ALS and frontotemporal dementia, and includes a research collaboration to develop other, similar medicines.

    By June 3, 2024
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Daniel Tadevosyan via Getty Images
    Image attribution tooltip
    News roundup

    FDA delays decision on Dupixent in COPD; Summit makes a bold claim

    Regeneron and Sanofi now expect an FDA verdict in September. Elsewhere, Summit claimed victory over Keytruda and Neurocrine’s longtime CEO revealed plans to step down.

    By BioPharma Dive staff • May 31, 2024
  • Antibodies autoimmune disease
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Immunovant changes up plans for closely watched autoimmune drugs

    The company is prioritizing development of an earlier so-called FcRn inhibitor, a type of medicine that’s shown promise treating multiple inflammatory conditions. 

    By Kristin Jensen • May 30, 2024
  • A stock market graph overlaid on a laptop and stack of coins.
    Image attribution tooltip
    Stadtratte via Getty Images
    Image attribution tooltip
    Emerging biotech

    CinCor’s ‘hub-and-spoke’ parent nabs new funding to build its next biotechs

    The $73 million round for CinRx Pharma, which created a startup AstraZeneca bought last year, will help fund subsidiaries making drugs for obesity, irritable bowel syndrome and gastroparesis. 

    By May 30, 2024